• A new study shows that Epstein-Barr virus infection is strongly linked to multiple sclerosis.
  • There is currently no cure to multiple sclerosis, and access to innovative treatments is limited in many countries.
  • Vaccinating for EBV instead could provide a more equitable path to treat and ultimately prevent the disease.

Several chronic or life-threatening diseases have their origin in a common viral or bacterial infection. Approximately two-thirds of the world population is infected with the bacterium Helicobacter pylori, which significantly increases the risk of developing gastric cancer. Similarly, high-risk types of human papillomavirus cause nearly all of cervical cancers. A recent large-scale study has now shown for the first time that Epstein-Barr virus (EBV) might be the main cause of multiple sclerosis. It is one of the most common human viruses: About 90% of people worldwide will be infected during their lifetime, generally causing few, if any, symptoms.

Multiple sclerosis (MS) is a chronic disease affecting the central nervous system (the brain and spinal cord). It occurs when the immune system attacks nerve fibres and myelin sheathing (a fatty substance which surrounds/insulates healthy nerve fibres) in the brain and spinal cord. This attack causes inflammation, which destroys nerve cell processes and myelin – altering electrical messages in the brain. MS is unpredictable and affects each patient differently – some individuals may be mildly affected, while others may lose their ability to write, speak or walk.

The risk of MS increased 32-fold after infection with EBV, but was unchanged after infection with other viruses, providing the first compelling evidence for EBV as the leading cause of the disease; something that has been suspected for many years.

These insights open a door to new prevention and treatment options for this uncurable disease or even an opportunity for eradication. Current MS-modifying treatments are costly and can exceed $70,000 per year in the US, with this significant spending limiting access and putting an additional burden on patients. Low- and middle-income countries suffer from significant access gaps, with poor availability of medications resulting for example in less than 35% of MS patients in Latin America having access to disease-modifying treatments.

Countries with the highest prevalence rates of multiple sclerosis as of 2015
Countries with the highest prevalence rates of multiple sclerosis as of 2015
Image: Statista

A vaccine against the initial Epstein-Barr virus could not only prevent the disease from developing, but also significantly reduce global healthcare costs, and improve equitable access and the sustainability of health systems. While there are currently no EBV vaccines on the market, the first clinical trials have recently been initiated. The exploratory vaccine is based on the new mRNA technology, which has delivered two successful COVID-19 vaccines.

Vaccines, Health and healthcare, Gavi

What is the World Economic Forum doing about access to vaccines?

In 2000, Gavi, the Vaccine Alliance was launched at the World Economic Forum's Annual Meeting in Davos, with an initial pledge of $750 million from the Bill and Melinda Gates Foundation.

The aim of Gavi is to make vaccines more accessible and affordable for all - wherever people live in the world.

Along with saving an estimated 10 million lives worldwide in less than 20 years,through the vaccination of nearly 700 million children, - Gavi has most recently ensured a life-saving vaccine for Ebola.

At Davos 2016, we announced Gavi's partnership with Merck to make the life-saving Ebola vaccine a reality.

The Ebola vaccine is the result of years of energy and commitment from Merck; the generosity of Canada’s federal government; leadership by WHO; strong support to test the vaccine from both NGOs such as MSF and the countries affected by the West Africa outbreak; and the rapid response and dedication of the DRC Minister of Health. Without these efforts, it is unlikely this vaccine would be available for several years, if at all.

Read more about the Vaccine Alliance, and how you can contribute to the improvement of access to vaccines globally - in our Impact Story.

The World Health Organization (WHO) considers vaccines to be one of the most successful and cost-effective public health interventions; equitable access to these vaccines will be crucial to deliver the full benefit across the globe. According to Dr Tedros Ghebreyesus, Director-General of the WHO, “vaccine equity is the challenge of our time”, yet “vaccine inequity is a solvable problem”.